1. EBV+ CNS LYMPHOMAS HAVE A DISTINCTIVE TUMOR MICROENVIRONMENT AND GENETIC PROFILE, WHICH IS AMENABLE TO COMBINATION 3RD PARTY EBV‐SPECIFIC CTL AND IBRUTINIB THERAPY. (12th June 2019) Authors: Gandhi, M.K.; Hoang, T.; Tobin, J.W.; Law, S.C.; Talaulikar, D.; Jain, S.; Vari, F.; Murigneux, V.; Fink, L.; Gunawardana, J.; Gould, C.; Oey, H.; Delecluse, S.; Trappe, R.U.; Merida de Long, L.; Sabdia, M.B.; Bhagat, G.; Hapgood, G.; Blyth, E.; Clancy, L. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗